Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial

Autor: Jones, J R, Cairns, D A, Gregory, W M, Collett, C, Pawlyn, C, Sigsworth, R, Striha, A, Henderson, R, Kaiser, M F, Jenner, M, Cook, G, Russell, N H, Williams, C, Pratt, G, Kishore, B, Lindsay, J, Drayson, M T, Davies, F E, Boyd, K D, Owen, R G, Jackson, G H, Morgan, G J

Publikováno v: Blood Cancer Journal

We have carried out the largest randomised trial to date of newly diagnosed myeloma patients, in which lenalidomide has been used as an induction and maintenance treatment option and here report its impact on second primary malignancy (SPM) incidence

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::7a75305c1f1d84ae49e97e7baf308021

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial.

Autor: Jones JR; The Institute of Cancer Research, London, UK.; The Royal Marsden Hospital NHS Foundation Trust, London, UK., Cairns DA; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK., Gregory WM; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK., Collett C; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK., Pawlyn C; The Institute of Cancer Research, London, UK.; The Royal Marsden Hospital NHS Foundation Trust, London, UK., Sigsworth R; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK., Striha A; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK., Henderson R; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK., Kaiser MF; The Institute of Cancer Research, London, UK.; The Royal Marsden Hospital NHS Foundation Trust, London, UK., Jenner M; Department of Haematology, University Hospital Southampton NHS Foundation Trust, Southampton, UK., Cook G; University of Leeds, Leeds, UK., Russell NH; Centre for Clinical Haematology, Nottingham University Hospital, Nottingham, UK., Williams C; Centre for Clinical Haematology, Nottingham University Hospital, Nottingham, UK., Pratt G; Heart of England NHS Foundation Trust, Birmingham, UK., Kishore B; Heart of England NHS Foundation Trust, Birmingham, UK., Lindsay J; Department of Haematology, East Kent Hospitals University NHS Foundation Trust, Kent, UK., Drayson MT; Clinical Immunology, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK., Davies FE; The Institute of Cancer Research, London, UK.; The Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA., Boyd KD; The Royal Marsden Hospital NHS Foundation Trust, London, UK., Owen RG; University of Leeds, Leeds, UK., Jackson GH; Department of Haematology, Newcastle University, Newcastle, UK., Morgan GJ; The Institute of Cancer Research, London, UK.; The Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

Publikováno v: Blood cancer journal [Blood Cancer J] 2016 Dec 09; Vol. 6 (12), pp. e506. Date of Electronic Publication: 2016 Dec 09.